Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Invobenitug in Cardiogenic Shock
NCT06832722Phase 2Recruiting
- Sponsor
- 4TEEN4 Pharmaceuticals
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 2 trial of invobenitug in cardiogenic shock, sponsored by 4TEEN4 Pharmaceuticals. Started Jul 2025; status: recruiting.
02
Drugs
invobenitug
03
Conditions
cardiogenic shock
Beyond the preview
Go deeper on NCT06832722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06832722.